In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 21 - 40 of 269In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...
Recently published in Nature Communications, PepQuery2 is a powerful tool that facilitates fast and targeted identification of both new and existing peptides in proteomics datasets obtained from mass spectrometry experiments. It...
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative...
The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted...
The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration...
Glycosylation is a ubiquitous type of protein modification that is associated with biological functions and diseases, including cancer. Often found on cell surface or secreted into circulation, glycoproteins can be leveraged for diagnosis and treatment.
Clear cell renal cell carcinoma (ccRCC) is a common type of kidney cancer that originates from the cells of the renal tubules. Recent research has focused on identifying tumor-cell-specific markers to provide mechanistic insights into cancer etiology and support the development of novel targeted...
Despite unprecedented advances in the development of targeted- and immuno-therapies for various cancer types, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related death worldwide. A comprehensive characterization of PDAC is critical for the development of new therapies...
Despite extensive clinical and scientific efforts, pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in Korea and around the world. Prior analyses of PDAC tissues have identified key genomic features of the disease, but proteomic signatures have not...
Diffuse intrinsic pontine gliomas (DIPG) are a type of brain tumor that is extremely aggressive and have a historically poor prognosis. To improve these outcomes, the development of novel therapies and methods to measure their efficacy are critical.
Renal cell carcinoma (RCC) is among the ten most diagnosed cancers worldwide for men and women and comprises a wide array of histologically and genetically defined subtypes involving the kidney. Clear cell RCC (ccRCC) accounts for ~75% of all RCC cases and the majority of renal cancer-associated...
Recently, Dr. Bing Zhang and his team from the Lester and Sue Smith Breast Center at Baylor College of Medicine were awarded a two-year funding opportunity to develop Cutting Edge Informatics Tools for the NIH Common Fund program Illuminating the Druggable Genome (IDG).
Core fucosylation (CF) of N-linked glycoproteins is linked with the functions of glycoproteins in many physiological and pathological processes. This feature has a high potential for use in the detection of cancer as well as the development of targeted therapies. For example, high levels of alpha-...
The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of a memorandum of understanding (MOU) bolstering its ongoing collaboration with the U.S. Food and Drug Administration (FDA). This MOU provides a framework that will enable and encourage the...
Genetic heterogeneity amongst leukemic cells is a major contributor to low survival rates and poor clinical outcomes for patients with acute myeloid leukemia (AML). This diversity drives complex signaling pathways at the protein level which necessitate individualized treatment protocols for each...
CPTAC investigators from Baylor College of Medicine and the Broad Institute of MIT and Harvard in collaboration with oncologists at Washington University in St. Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy...
The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of partnerships with Australia, Canada, and Germany. These partnerships, through memoranda of understanding (MOUs) to the NCI Cancer Moonshot International...
CPTAC investigators from Washington University School of Medicine in St. Louis have developed new multiplexed assays for analyzing kinase proteins by parallel reaction monitoring mass spectrometry (PRM), a targeted form of mass spectrometry that enables highly sensitive and specific measurements. The...
This year, the 8th Annual FedHealthIT Innovation Awards recognized programs from the Department of Veterans Affairs, Military Health, Health and Human Services, and Centers for Medicare and Medicaid Services. These programs were carefully selected by their peers for their commitment to excellence,...